Ticker
ADCT

Price
4.82
Stock movement down
-0.47 (-8.88%)
Company name
Adc Therapeutics SA
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
388.70M
Ent value
502.70M
Price/Sales
1.85
Price/Book
4.38
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
11.57%
3 year return
-46.55%
5 year return
-
10 year return
-
Last updated: 2024-02-20

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

ADCT does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales1.85
Price to Book4.38
EV to Sales2.39

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count80.64M
EPS (TTM)-1.93
FCF per share (TTM)-1.72

Income statement

Loading...
Income statement data
Revenue (TTM)209.91M
Gross profit (TTM)205.33M
Operating income (TTM)-123.63M
Net income (TTM)-155.80M
EPS (TTM)-1.93
EPS (1y forward)-2.61

Margins

Loading...
Margins data
Gross margin (TTM)97.82%
Operating margin (TTM)-58.90%
Profit margin (TTM)-74.22%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash326.44M
Net receivables72.97M
Total current assets446.01M
Goodwill0.00
Intangible assets14.36M
Property, plant and equipment0.00
Total assets529.17M
Accounts payable12.35M
Short/Current long term debt117.38M
Total current liabilities98.96M
Total liabilities440.44M
Shareholder's equity88.73M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-136.79M
Capital expenditures (TTM)650.00K
Free cash flow (TTM)-138.33M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-175.59%
Return on Assets-29.44%
Return on Invested Capital-78.08%
Cash Return on Invested Capital-69.33%

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open5.43
Daily high6.04
Daily low4.73
Daily Volume1.80M
All-time high51.05
1y analyst estimate11.14
Beta1.22
EPS (TTM)-1.93
Dividend per share-
Ex-div date-
Next earnings date26 Feb 2024

Downside potential

Loading...
Downside potential data
ADCTS&P500
Current price drop from All-time high-90.56%-1.05%
Highest price drop-99.08%-56.47%
Date of highest drop9 Nov 20239 Mar 2009
Avg drop from high-67.42%-11.40%
Avg time to new high59 days13 days
Max time to new high914 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
ADCT (Adc Therapeutics SA) company logo
Marketcap
388.70M
Marketcap category
Small-cap
Description
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; and LOTIS-7, a Phase Ib clinical trial for treatment of relapsed or refractory B-cell lineage non-hodgkin lymphoma (B-NHL). The company is also developing camidanlumab tesirine, an ADC composed of a monoclonal antibody that binds to CD25 conjugated to a PBD"dimer toxin, as well as in Phase II clinical trial in relapsed or refractory hodgkin lymphoma. In addition, it develops ADCT-602, which is in Phase I/II clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 that are in Phase Ia clinical trial for treatment of various solid tumors and hematological malignancies; and ADCT-212, a second-generation PBD-based ADC targeting prostate-specific membrane antigen (PSMA), including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Employees
317
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...